Indonesia National Agency for Drug and Food Control, BPOM, Approved QDENGA(TAK-003) for Use in Individuals Six Years to 45 Years of Age1 QDENGAis the Only Dengue Vaccine Approved in Indonesia for Use
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company
Achieved Global Recognition and Top Employer Certification in 22 Countries from Top Employers Institute − Global Recognition Reinforces Commitment to People and Outstanding People Policies Takeda (TS
EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study – Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating EXKIVITY’
− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to
− Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology − Oral Presentations Include Updated Results from Phase 3 OPTIC Trial of ICLUSIG® (ponatinib) and
Q1 FY2022 Results Demonstrate a Strong Start to the Year with Core Revenue Growth at Constant Exchange Rate (CER) of +8.3% (Reported Revenue +2.4%) Growth and Launch Products Delivering Revenue Growth
/newsonfloor/media/post_banners/reFeJd3BrWxMnk3F6gju.jpg)
![Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure](https://img-cdn.thepublive.com/fit-in/560x320/filters:format(webp)/newsonfloor/media/post_banners/KxvmBU83yvYyxhjYKE5z.jpg)
/newsonfloor/media/post_banners/NKkH7cu1aAFOSoRW87hE.jpg)
/newsonfloor/media/post_banners/ufnAoqvsJt8crZrLmnvL.jpg)
/newsonfloor/media/post_banners/Sf5S1VIGUZrbLXd4JJrj.jpg)
/newsonfloor/media/post_banners/8etqEmbMo1yxibyZl33D.jpg)
/newsonfloor/media/post_banners/v5lIoAtwmYrAR5I4OPXg.jpg)
/newsonfloor/media/post_banners/yuKeToENsOtrLzPFSevM.jpg)
/newsonfloor/media/post_banners/RnHO7Dq0mMVof0rtrt2G.jpg)
/newsonfloor/media/post_banners/FDMARIrZTfOcInOqMbxM.jpg)
